On Wednesday, Mizuho (NYSE:MFG) Securities reiterated their Outperform rating on GE HealthCare (NASDAQ:GEHC) Technologies Inc. (NASDAQ: GEHC), with a steady price target of $105.00. The affirmation comes as GE HealthCare prepares to host its Analyst Day on Thursday, November 21, from 8 to 11 am EST at the NASDAQ.
The financial institution anticipates several key updates from the event. Among the expected highlights are the release of a new long-range plan (LRP) and insights on the latest market trends in China following recent stimulus measures and the outcomes of the U.S. elections. Additionally, GE HealthCare is expected to share launch plans and reimbursement timelines for Flyrcado, its F-18 tracer for cardiac amyloidosis imaging.
The Analyst Day is also set to provide an outlook on Vizamyl, used in PET imaging for Alzheimer's disease, particularly in light of positive trends surrounding Biogen (NASDAQ:BIIB)'s LEQEMBI. Furthermore, GE HealthCare is likely to discuss the impact of AI-enabled software on its business, focusing on key applications and potential economic models.
Mizuho also anticipates updates on the imaging segment and the overall margin outlook as part of the updated LRP. Finally, GE HealthCare is expected to outline its capital allocation priorities moving forward. The firm notes that with the stock currently trading at a discount compared to its peers, the current price level presents an attractive entry point into a high-quality large-cap equity story.
In other recent news, GE HealthCare has been making significant strides in its operations and financial performance. The company reported a 1% organic revenue growth in the recent quarter, with total revenues reaching $4.9 billion. The adjusted EBIT margin improved to 16.3%, and adjusted EPS rose to $1.14, marking a 15% year-over-year increase. The company's backlog now stands at $19.6 billion, largely due to service contracts and multiyear enterprise deals.
GE HealthCare's SIGNA MAGNUS, a head-only 3.0T MRI scanner, has obtained FDA 510(k) clearance, marking a notable advancement in magnetic resonance imaging technology, particularly for neuroimaging. The company also plans to launch Flyrcado, a new PET imaging agent expected to generate annual revenues of over $500 million.
Piper Sandler has affirmed its Overweight rating on GE HealthCare's shares, indicating confidence in its value-creating strategies. The firm's analysts anticipate that the upcoming Investor Day will shed light on GE HealthCare's advancements, including its radiopharmaceutical portfolio and artificial intelligence efforts.
Amid these recent developments, GE HealthCare has raised its full-year guidance for adjusted EBIT margin to 15.8%-16% and adjusted EPS to $4.25-$4.35.
InvestingPro Insights
GE HealthCare Technologies Inc. (NASDAQ: GEHC) continues to show promise as a prominent player in the Healthcare Equipment & Supplies industry, aligning with Mizuho Securities' Outperform rating. InvestingPro data reveals that GEHC has a market capitalization of $37.7 billion and a P/E ratio of 22.72, indicating investor confidence in its future earnings potential.
The company's financial health appears robust, with revenue of $19.56 billion over the last twelve months and a gross profit margin of 41.34%. This solid financial foundation supports GE HealthCare's ability to invest in new technologies and product launches, such as Flyrcado and AI-enabled software, which are expected to be discussed at the upcoming Analyst Day.
InvestingPro Tips highlight that GEHC is predicted to remain profitable this year, which is crucial as the company outlines its long-range plan and capital allocation priorities. The stock's low price volatility could be attractive to investors seeking stability in the healthcare sector.
It's worth noting that InvestingPro offers 6 additional tips for GEHC, providing investors with a more comprehensive analysis of the company's prospects. These insights could be particularly valuable as the market anticipates updates on market trends, product launches, and margin outlooks from the Analyst Day.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.